NO995697L - Gene vectors - Google Patents

Gene vectors

Info

Publication number
NO995697L
NO995697L NO995697A NO995697A NO995697L NO 995697 L NO995697 L NO 995697L NO 995697 A NO995697 A NO 995697A NO 995697 A NO995697 A NO 995697A NO 995697 L NO995697 L NO 995697L
Authority
NO
Norway
Prior art keywords
adenovirus
tissue tropism
analogue
nucleic acid
delivery vehicle
Prior art date
Application number
NO995697A
Other languages
Norwegian (no)
Other versions
NO995697D0 (en
Inventor
Ronald Vogels
Menzo Jans Emco Havenga
Abraham Bout
Original Assignee
Introgene Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgene Bv filed Critical Introgene Bv
Publication of NO995697D0 publication Critical patent/NO995697D0/en
Publication of NO995697L publication Critical patent/NO995697L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Abstract

The invention provides a nucleic acid delivery vehicle with or having been provided with at least a tissue tropism for smooth muscle cells and/or endothelial cells. In one aspect said nucleic acid delivery vehicle is a virus capsid or a functional part, derivative and/or analogue thereof. Preferably said virus capsid is an adnovirus capsid. Preferably said adenovirus is a subgroup B adenovirus, preferably adenovirus 16. Preferably said tissue tropism is provided by at least a tissue tropism determining part of an adenovirus fiber protein or a functional derivative and/or analogue thereof. The invention further presents methods for the treatment of diseases, preferably cardiovascular diseases.
NO995697A 1998-11-20 1999-11-19 Gene vectors NO995697L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98203921 1998-11-20

Publications (2)

Publication Number Publication Date
NO995697D0 NO995697D0 (en) 1999-11-19
NO995697L true NO995697L (en) 2000-05-22

Family

ID=8234363

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995697A NO995697L (en) 1998-11-20 1999-11-19 Gene vectors

Country Status (12)

Country Link
JP (1) JP4683682B2 (en)
AT (1) ATE296894T1 (en)
AU (1) AU770780B2 (en)
CA (1) CA2318492C (en)
DE (1) DE69925567T2 (en)
ES (1) ES2244145T3 (en)
IL (1) IL133032A (en)
MX (1) MXPA99010682A (en)
NO (1) NO995697L (en)
NZ (1) NZ501214A (en)
WO (1) WO2000031285A1 (en)
ZA (1) ZA997213B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1159438B1 (en) * 1999-03-04 2008-07-30 Crucell Holland B.V. Use of adenoviral vector for synovial cell transduction
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
JP2003534805A (en) 2000-05-31 2003-11-25 ユニバーシティ オブ サスカチュワン Modified bovine adenovirus with altered affinity
EP1322774A2 (en) * 2000-09-20 2003-07-02 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for dendritic cells
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
EP1482052A1 (en) * 2003-05-27 2004-12-01 Cytos Biotechnology AG Modified polypeptides for targeting cell-entry of the adenoviruses of subtype B
JP7216668B2 (en) 2017-05-26 2023-02-01 エピセントアールエックス，インコーポレイテッド Recombinant adenovirus carrying the transgene

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
AU731767B2 (en) * 1995-06-15 2001-04-05 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL124654A0 (en) * 1995-11-28 1998-12-06 Genvec Inc Vectors and method for gene transfer to cells
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
FR2758822B1 (en) * 1997-01-30 1999-07-02 Centre Nat Rech Scient USE OF A POLYPEPTIDE AS A CELLULAR RECEPTOR OF ADENOVIRUS
FR2761689B1 (en) * 1997-04-02 1999-06-25 Transgene Sa MODIFIED ADENOVIRAL FIBER AND TARGET ADENOVIRUS

Also Published As

Publication number Publication date
ZA997213B (en) 2000-05-22
IL133032A (en) 2007-06-03
CA2318492A1 (en) 2000-06-02
CA2318492C (en) 2010-05-11
NO995697D0 (en) 1999-11-19
DE69925567T2 (en) 2006-05-04
NZ501214A (en) 2002-02-01
WO2000031285A1 (en) 2000-06-02
DE69925567D1 (en) 2005-07-07
AU770780B2 (en) 2004-03-04
JP4683682B2 (en) 2011-05-18
IL133032A0 (en) 2001-03-19
ATE296894T1 (en) 2005-06-15
JP2000157289A (en) 2000-06-13
ES2244145T3 (en) 2005-12-01
MXPA99010682A (en) 2002-03-08
AU5960099A (en) 2000-05-25

Similar Documents

Publication Publication Date Title
ATE403006T1 (en) USE OF AN ADENOVIRUS VECTOR FOR TRANSDUCING SYNOVIAL CELLS
ES2156958T3 (en) ADENOVIRUS-AAV HYBRID VIRUS AND SAME USE METHOD.
ATE231549T1 (en) METHOD FOR PRESERVING INFECTIOUS RECOMBINING VIRUSES, VIRAL AQUEOUS SUSPENSION AND MEDICAL USE THEREOF
ATE405295T1 (en) IMPROVED RAAV EXPRESSION SYSTEMS FOR GENETIC MODIFICATION OF SPECIFIC CAPSID PROTEINS
DE59913833D1 (en) STRUCTURAL PROTEIN OF AAV, ITS MANUFACTURE AND USE
FR11C0027I2 (en) RECOMBINANT INFLUENZA VIRUSES FOR VACCINES AND GENETIC TREATMENT
HK1020756A1 (en) Use of angiogenic factor vegf145 in treating cardiovascular disease
ES2086997T3 (en) OLIGONUCLEOTIDE-ALKYLPHOSPHONATES AND -ALKYLPHOSPHONOTIOATES.
EP1005376A4 (en) Methods and compositions for use in gene therapy for treatment of hemophilia
WO2001005434A3 (en) Hyaluronic acid-protein conjugates
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
NO995697D0 (en) Gene vectors
JP2002537816A5 (en)
ATE214708T1 (en) CATIONIC AGENTS FOR TRANSFECTION OF NUCLEIC ACIDS
FR2600079B1 (en) VIRAL VECTOR AND RECOMBINANT DNA ENCODING PROTEIN F OF THE VIRUS CAUSAL AGENT OF THE S.I.D.A, CELL CULTURE INFECTED WITH THIS VECTOR, PROCESS FOR PREPARING THE PROTEIN, OBTAINED PROTEIN, VACCINE AND ANTIBODIES OBTAINED
ATE331794T1 (en) HUMAN PROSTACYCLIN SYNTHASE
FR2756491B1 (en) TRANSFECTING COMPOSITION USEFUL IN GENE THERAPY ASSOCIATED WITH A RECOMBINANT VIRUS INCORPORATING EXOG ENE NUCLEIC ACID, A NON-VIRAL AND NON-PLASMIDIC TRANSFECTING AGENT
WO1999031136A3 (en) Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells
AU1281902A (en) Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
FI964784A0 (en) Virus recombinants, preparation and use in gene therapy
DE69829174D1 (en) EXPRESSION OF A MODIFIED "FOAMY VIRUS ENVELOPE PROTEIN" (SLEEP PROTEIN)
FR2743818B1 (en) DNA CONSTRUCTS AND EXPRESSION VECTORS DERIVED FROM THE VA RNA GENE OF ADENOVIRUS
WO2002029073A3 (en) Gene delivery vectors for stem cells

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application